CONCLUSIONS: iTBS is effective for MDD in routine clinical practice; however, its therapeutic impact appears moderately reduced in patients with ASD and/or ADHD. These findings underscore the need for individualized neuromodulation strategies and further investigation into neurobiological and sensory factors contributing to treatment heterogeneity.
